To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

NCT00294723 · Terminated

Last updated 2026-05-28

This clinical trial compares the effects of the medication liraglutide to glimepiride (Amaryl®) on blood sugar control, measured by HbA1c levels, in adults with type 2 diabetes over 52 weeks.

Status Terminated Stopped early and will not restart.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 746 people

Who can join Ages 18–80 · all sexes

Timeline Started 2006-02 · est. completion 2008-11

Where 117 sites · Mexico, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT00294723 ↗

Description as written by the study sponsor.

This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).

Treatments tested

liraglutide Drug

1.8 mg for s.c. (under the skin) injection
glimepiride Drug

8 mg capsule
liraglutide Drug

1.2 mg for s.c. (under the skin) injection
placebo Drug

Glimepiride placebo, 8mg capsule
placebo Drug

Liraglutide placebo, 200 mcl
placebo Drug

Liraglutide placebo, 300 mcl

Main thing measured	Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00294723 ↗